An observational study in Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Methodist Health System. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Methodist Health System · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States — 7 open to participants now, 16 under way, 5 of them phase 3. Gastro-enteropancreatic neuroendocrine tumor · United States.
Among the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States, this one is one of 3 that started in 2024, is one of 8 observational ones, reaches primary completion later than 4 of the 15 other live ones, and was the 12th registered.
73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.
Browse Gastro-enteropancreatic neuroendocrine tumor studies →7 of the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–110
RayzeBio, Inc. · Sites in United States, Canada
Ages 18+
Emory University · Sites in United States
Ages 18+
ITM Solucin GmbH · Sites in United States, France, Spain
Ages 24 mo–18 yrs
Novartis Pharmaceuticals · Sites in United States, Canada, China and 9 more countries
Ages 12–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Gastro-enteropancreatic neuroendocrine tumor studies recruiting now, 13 (62%) set no upper age limit and 4 (19%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 5
First in 2011; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 164 across 21 observational studies indexed under Gastro-enteropancreatic neuroendocrine tumor.
Median enrollment 21 across the 22 interventional studies, 75 across the 8 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Methodist Health System has 1 study filed under Gastro-enteropancreatic neuroendocrine tumor — fewer than ten, so there is no comparison to draw.
6 of the studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05050942Phase 3Camurus ABA Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | 2026-11 |
| NCT05477576Phase 3RayzeBio, Inc.Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | 2026-12 |
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT04609592Stanford UniversityStudy of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | 2026-11 |
| NCT07165132RayzeBio, Inc.Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
Neuroendocrine tumors (NETs) make up a large range of malignancies that arise from neuroendocrine cells in multiple organs of the body. Hallet et al conducted a large population-based study that demonstrated that 21% of NET patients presented with metastatic disease and another 38% developed metastases after resection of the primary tumor (Hallet et al., 2015). This burden demonstrates the need for effective systemic therapy for advanced NETs. Options for systemic therapy include peptide receptor radionuclide therapy (PRRT).
A need for more prospective series are needed on treatment responses and survival outcomes related to gastroenteropancreatic primary NETs treated with PRRT was identified. Thus the purpose of this study is to collect clinical data related to treatment of gastroenteropancreatic primary NETs s with PRRT. Clinical data related to patient characteristics, treatment responses and survival outcomes related to the treatment of gastroenteropancreatic primary NETs with PRRT and on adverse events and complications related to PRRT treatment will be collected.
73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.
This study's planned enrollment of 50 is below the median of 164 across 21 observational studies indexed under Gastro-enteropancreatic neuroendocrine tumor.
Browse Gastro-enteropancreatic neuroendocrine tumor studies →Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Compared within Gastro-enteropancreatic neuroendocrine tumor, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neuroendocrine Tumors. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients will be screened for NETs per standard of care. Those patients, who have or will undergo the PRRT procedure, will be offered the opportunity to participate in this registry study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:
Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.
Procedure: Peptide Receptor Radionuclide Therapy
a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
Demographics and other patient data
(such as age at diagnosis, sex, history of smoking alcohol use and symptoms at the time of diagnosis)
Time frame: 7 years from date of procedure
Tumor specific data
Tumor site, tumor grade, stage, presence of tumor necrosis, number of mitoses and percentage of Ki-67 and MIB-1 positive cells (proliferative index)
Time frame: 7 years from date of procedure
Use of somatostatin analogs
at the time of PRRT, location, isotope used and dose of isotope for each PRRT
Time frame: 7 years from date of procedure
Biomarker data (chromogranin A and pancreastatin)
at the time of diagnosis, before and after the first PRRT, and after the second PRRT were also extracted
Time frame: 7 years from date of procedure
Diagnostic imaging findings
prior to PRRT and response after PRRT, date of progression on imaging after PRRT, and status of disease on imaging at the last follow-up were also recorded
Time frame: 7 years from date of procedure
Overall survival (OS)
the time from diagnosis to death of any cause.
Time frame: 7 years from date of procedure
Time to progression (TTP)
the time from the first PRRT until any progression on diagnostic imaging
Time frame: 7 years from date of procedure
Treatment responses and progression
assessed with cross-sectional imaging with either computerized tomography (CT) or magnetic resonance imaging (MRI) or positron emission tomography (PET) or single-photon emission computed tomography (SPECT).
Time frame: 7 years from date of procedure
Response
any response of any magnitude
Time frame: 7 years from date of procedure
Disease progression
any increase in lesion sizes and/or appearance of new metastatic lesions on diagnostic imaging exams.
Time frame: 7 years from date of procedure
Adverse events
will be assessed by the investigator who will determine whether or not the event is related to PRRT or related to progression of disease (gastroenteropancreatic primary NET), and whether or not the event meets serious criteria. AEs related to PRRT will be recorded in the study registry.
Time frame: 7 years from date of procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Jun 2026, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gastro-enteropancreatic neuroendocrine tumor →